The final patient completes Phase I trial
enrollment, evaluating safety and tolerability for Biomica's
microbiome-based immuno-oncology drug, BMC128
REHOVOT, Israel, Jan. 17,
2024 /PRNewswire/ -- Biomica Ltd., a
clinical-stage biopharmaceutical company developing innovative
microbiome-based therapeutics and a subsidiary of Evogene Ltd.
(Nasdaq: EVGN) (TASE: EVGN), today announced that the final patient
has been enrolled in its Phase I clinical trial.
Initiated on July 11, 2022, the
Phase I trial was specifically designed to evaluate the safety and
tolerability of Biomica's microbiome-based immuno-oncology drug
candidate, BMC128, in combination with immune checkpoint inhibitor
(ICI) immunotherapy, in patients with either non-small cell lung
cancer (NSCLC), melanoma or renal cell carcinoma (RCC), who
previously progressed on immunotherapy. Bristol Myers Squibb's Opdivo® is the immune checkpoint
inhibitor in the trial. The study takes place at The Davidoff
Center and the Rambam Health Care Campus in Israel.
Biomica remains on track with preliminary results, and the first
data point readout is expected in H1 2024.
Dr. Elran Haber, CEO of Biomica, stated: "We are
pleased to complete the Phase 1 Proof of Concept study enrollment,
marking a critical step forward in developing our groundbreaking
BMC128. We are excited about the progress made thus far and
confident about the potential of BMC128 to address the unmet needs
in the treatment of ICI-refractory cancer patients."
About BMC128:
BMC128 is a rationally designed microbial consortium identified
and selected through a detailed functional microbiome analysis
using PRISM, a proprietary high-resolution microbiome analysis
platform powered by MicroBoost AI tech engine.
Developed as a Live Bacterial Product (LBP), BMC128 is an LBP
consortium comprised of four unique bacterial strains, natural
inhabitants of the human intestinal tract, that harbor specific
functional capabilities with the potential to enhance immunological
therapeutic responses and facilitate anti-tumor immune activity
through multiple biological processes.
Rationally-designed consortia are multi-strain products designed
to restore diversity and specific functionality to a host's
microbial community with individually selected, cultured
bacteria.
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing PRISM system, a
proprietary computational platform powered by Evogene's MicroBoost
AI tech-engine. licensed from Evogene. Biomica aims to identify and
characterize disease-related microbiome entities and to develop
novel therapeutics based on these understandings. The company is
focused on the development of therapies for antibiotic resistant
bacteria, immuno-oncology, and microbiome-related gastrointestinal
(GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq:
EVGN, TASE: EVGN).
For more information, please visit www.biomicamed.com.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of
life-science-based products by utilizing cutting-edge technologies
to increase the probability of success while reducing development
time and cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass AI, and GeneRator AI –
leveraging Big Data and Artificial Intelligence and incorporating
deep multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of products
based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Evogene
and its subsidiaries are using forward-looking statement in this
press release when it discusses safety and tolerability of
Biomica's microbiome-based immuno-oncology drug candidate, BMC128,
in combination with immune checkpoint inhibitor (ICI) immunotherapy
and the success of BMC128 to address the unmet needs in the
treatment of ICI-refractory cancer patients and the expected timing
of the first data point readout in H1 2024. Such statements are
based on current expectations, estimates, projections and
assumptions, describe opinions about future events, involve certain
risks and uncertainties which are difficult to predict and are not
guarantees of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, the current war between Israel and Hamas and any worsening of the
situation in Israel such as
further mobilizations or escalation in the northern border of
Israel, and those risk factors
contained in Evogene's reports filed with the applicable securities
authority. In addition, Evogene and its subsidiaries rely, and
expect to continue to rely, on third parties to conduct certain
activities, such as their field-trials and pre-clinical studies,
and if these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet
expected deadlines, Evogene and its subsidiaries may experience
significant delays in the conduct of their activities. Evogene and
its subsidiaries disclaim any obligation or commitment to update
these forward-looking statements to reflect future events or
developments or changes in expectations, estimates, projections,
and assumptions.
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1974949/Biomica_Logo.jpg
Logo -
https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-successfully-completes-phase-i-trial-enrollment-for-microbiome-based-immuno-oncology-drug-302036967.html
SOURCE Biomica Ltd.